Effect of empagliflozin 12 months after drug eluting stent implantation in type 2 diabetics with stable angina.

Not Applicable

• Conditions: Ischemic heart disease, Type 2 diabetes mellitus

• Registration Number: JPRN-UMIN000039079
• Lead Sponsor: Department of Cardiology, NTT Medical Center Tokyo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-01-10
• Study Start: 2020-01-08
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Use of SGLT-2 inibitor at baseline Use of insulin Patients with moderate or severe chronic kidney disease (eGFR <45) Patients with ST elevated myocardial infarction, chronic total occlusion, significant left main lesion, in-stent restenosis lesion Endocrine and gastrointestinal disorders Hepatic dysfunction (Child-Pugh score > 10) Patients with malignancy Patients with type 1 diabetes

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison of neointimal tissue 12 months after drug eluting stent between diabetes patients with empagliflozin treatment and standard therapy; evaluated by optical coherence tomography.

Secondary Outcome Measures

Name	Time	Method
The changes of ultrasound cardiography finding 12 months after intervention. The changes of physical examination and laboratory findings including glucose (fasting glucose level, 1.5 AG, HbA1c),lipid parameter and inflamattory cytokine (hsCRP).